| |
 |
Schering Corporation Patents |
|
Assignee: Schering Corporation
Address: Kenilworth, NJ
No. of patents: 1443
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| RE39015 |
DNA encoding interleukin-B30 |
March 14, 2006 |
| Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using the reagents and diagnostic kits are also provided. |
| RE37721 |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
May 28, 2002 |
| Hydroxy-substituted azetidinone hypocholesterolemic agents of the formula ##STR1##or a pharmaceutically acceptable salt thereof, wherein:Ar.sup.1 and Ar.sup.2 are aryl or R.sup.4 -substituted aryl;Ar.sup.3 is aryl or R.sup.5 -substituted aryl;X, Y and Z are --CH.sub.2 --, --CH(lower alkyl)-- or |
| RE32465 |
AZA penem compounds |
July 28, 1987 |
| Described is a novel process for the preparation of penems and carbapenems useful as antibacterial agents which comprises the reaction of an appropriate 4-substituted-azetidine-2-one with an acid halide in the presence of a tertiary amine and an alkaline earth metal carbonate, follow |
| RE31422 |
Hydrophilic polymers and contact lenses of high water content |
October 18, 1983 |
| Cross-linked hydrophilic interpolymers and contact lenses made therefrom comprising hydrophilic units of which the only or major proportion are derived from .Iadd.vinyl pyridine or .Iaddend.an N-vinyl heterocyclic monomer, hydrophobic units derived from the group consisting of styrene |
| D471831 |
Counting device |
March 18, 2003 |
|
| D471830 |
Counting device |
March 18, 2003 |
|
| D471120 |
Counting device |
March 4, 2003 |
|
| D422782 |
Heel cushion with insert |
April 18, 2000 |
|
| D387874 |
Syringe tray |
December 16, 1997 |
|
| D383535 |
Tablet |
September 9, 1997 |
|
| D355844 |
Bottle |
February 28, 1995 |
|
| D350193 |
Combined inhaler and cover |
August 30, 1994 |
|
| D349572 |
Aerosol inhaler |
August 9, 1994 |
|
| D348928 |
Inhaler |
July 19, 1994 |
|
| D345013 |
Combined inhaler and cover |
March 8, 1994 |
|
| D344797 |
Combined inhaler and cover |
March 1, 1994 |
|
| D344796 |
Combined inhaler and cover |
March 1, 1994 |
|
| D308100 |
Nasal spray pump |
May 22, 1990 |
|
| D307646 |
Cosmetic powder container |
May 1, 1990 |
|
| D294063 |
Vaginal applicator |
February 2, 1988 |
|
| D285375 |
Poultry vaccination unit |
August 26, 1986 |
|
| D270283 |
Nasal nozzle |
August 23, 1983 |
|
| D267587 |
Plunger rod/needle protector for a hypodermic syringe |
January 11, 1983 |
|
| 7414058 |
Adenosine A.sub.2a receptor antagonists for the treatment of extra-pyramidal syndrome and other |
August 19, 2008 |
| There is disclosed a method for the treatment of Extra Pyramidal syndrome (EPS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS. |
| 7411041 |
DCRS5 polypeptides |
August 12, 2008 |
| Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. |
| 7405223 |
Treating allergic and inflammatory conditions |
July 29, 2008 |
| A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of deslor |
| 7399749 |
Substituted prolines as inhibitors of hepatitis C virus NS3 serine protease |
July 15, 2008 |
| The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat |
| 7396929 |
Synthesis of 3-amino-4-substituted pyrazole derivatives |
July 8, 2008 |
| This application discloses a novel process to synthesize 3-amino-4-substituted pyrazole derivatives, which may be used, for example, as intermediates to prepare compounds having, for example, pharmaceutical utility. |
| 7393631 |
Method for purifying adenoviruses |
July 1, 2008 |
| Methods for purifying adenoviruses from a contaminated sample using a hydroxyapatite medium are provided. Sodium chloride concentrations present in buffers used throughout the method are at least 150 mM to prevent the adenovirus from irreversibly binding to the hydroxyapatite. Levels |
| 7393530 |
IL-1-like cytokine antibodies |
July 1, 2008 |
| Nucleic acids encoding mammalian, e.g., primate, IL-1.zeta., purified IL-1.zeta. polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are |
| 7390652 |
Device for cultivating cells and propagating viruses |
June 24, 2008 |
| This invention relates to methods for the cultivating cells, and in particular to methods for propagating viruses. |
| 7390481 |
Mammalian cytokine complexes |
June 24, 2008 |
| Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. |
| 7387794 |
Preparation of powder agglomerate |
June 17, 2008 |
| The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. |
| 7384948 |
Piperidine derivatives useful as CCR5 antagonists |
June 10, 2008 |
| The present invention provides a compound of the formula ##STR00001## or a pharmaceutically acceptable salt or solvate thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.9, R.sup.10, A and B are as defined in the specification. The present invention also provides pharmaceutical compo |
| 7384944 |
Piperazine derivatives useful as CCR5 antagonists |
June 10, 2008 |
| The use of CCR5 antagonists of the formula ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R.sup.1 is hydrogen or alkyl; R.sup.2 is substituted phenyl, substituted heteroaryl, naphthyl, fluore |
| 7378518 |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses there |
May 27, 2008 |
| The present invention provides compounds represented by the structural formula (I): ##STR00001## or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above |
| 7368563 |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses there |
May 6, 2008 |
| The present invention provides compounds represented by the structural formula (I): ##STR00001## or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations iucluding the above |
| 7368562 |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses there |
May 6, 2008 |
| The present invention provides compounds represented by the structural formula (I): ##STR00001## or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above |
| 7368457 |
Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors |
May 6, 2008 |
| In an embodiment, this invention discloses novel gamma secretase inhibitors of Formulae I: ##STR00001## wherein the various moieties are described herein. Also disclosed is a method of treating Alzheimer's disease using a compound of Formula I or a composition comprising the compoun |
| 7368449 |
2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A.sub. |
May 6, 2008 |
| Compounds having the structural formula I ##STR00001## or a pharmaceutically acceptable salt thereof, wherein R is ##STR00002## R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are H, alkyl or alkoxyalkyl; R.sup.6 is H, alkyl, hydroxyalkyl or --CH.sub.2F; R.sup.7, R.sup.8 and R.s |
| 7361769 |
Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment |
April 22, 2008 |
| The present invention discloses compounds of formula I ##STR00001## wherein m, n, p, R.sup.1, R.sup.2 and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the |
| 7358352 |
Nucleic acids encoding human TNF-.alpha. convertase |
April 15, 2008 |
| The present invention provides isolated human and bovine TNF-.alpha. convertases, nucleic acids and; recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods for making the convertases using the host cells. This invention further provide |
| 7357924 |
Uses of IL-174 for treating helminth infections |
April 15, 2008 |
| Use of the cytokine designated IL-174 to treat infectious diseases such as helminth infections. |
| 7354922 |
Bridged ring NK.sub.1 antagonists |
April 8, 2008 |
| A compound having the general structure shown in Formula (I): ##STR00001## or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, includ |
| 7354921 |
Pyrazolotriazines as kinase inhibitors |
April 8, 2008 |
| In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]triazine compounds as inhibitors of kinases such as, for example, cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, |
| 7354705 |
Methods for cancer prognosis and diagnosis |
April 8, 2008 |
| The invention provides methods for prognosis and diagnosis in human cancer patients comprising detecting in human tumor tissues the infiltration of certain immune cells associated with poor cancer prognosis. The methods are useful for making clinical decisions on cancer treatment, su |
| 7348328 |
MCH antagonists for the treatment of obesity |
March 25, 2008 |
| The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as metho |
| 7345042 |
MCH antagonists for the treatment of obesity |
March 18, 2008 |
| The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). I |
| 7342103 |
DIRS1 antibodies |
March 11, 2008 |
| The present invention provides nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof, and antibodies against these receptor proteins. Methods of using these compositions for both diagnostic and therapeutic utilities are also |
| 7342041 |
3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease |
March 11, 2008 |
| The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat |
|
|
|
